New Approach Methodologies (NAMs): By the numbers Guide New Approach Methodologies (NAMs): By the numbers We outline today’s animal-use landscape, the rise of NAMs, & how the Non-Animal Navigator supports…CertaraDecember 10, 2025
QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™ Live Events QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™ Japan: February 26, 2026 - 1:00 - 5:00 pm | Korea: Wednesday, March 4, 2026…CertaraDecember 9, 2025
Virtual Triplets: The Next Step in Personalized and Ethical Drug Development Blog Virtual Triplets: The Next Step in Personalized and Ethical Drug Development Learn how virtual triplets, linking PBPK, QSP, and organ-on-a-chip technologies, are transforming model-informed drug development,…CertaraDecember 9, 2025
Expedited Pharmacometrics Regulatory Submissions Fact Sheet Expedited Pharmacometrics Regulatory Submissions Certara delivers complete, compliant pharmacometric regulatory submission packages in just 4–6 weeks, eliminating the PMx…CertaraDecember 8, 2025
Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings Announcement Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings Certara launches an expedited Pharmacometrics (PMx) Regulatory Submission service that cuts submission timelines in half.CertaraDecember 3, 2025
History and Evolution of Innovations in Clinical Pharmacology Publication History and Evolution of Innovations in Clinical Pharmacology This paper reviews how decades of scientific and technological advances have transformed clinical pharmacology and…Danielle PillsburyNovember 26, 2025
Modeling amyloid plaque turnover dynamics improves characterization of drug effects Publication Modeling amyloid plaque turnover dynamics improves characterization of drug effects Researchers modeled how amyloid plaques form and clear in Alzheimer’s disease, helping explain how treatments…CertaraNovember 26, 2025
The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation Blog The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation The stepwise Paediatric Investigation Plan (PIP) is a strategic, flexible route for drug developers navigating…CertaraNovember 26, 2025
Using M&S to Evaluate Oncology Drug Dosing Blog Using M&S to Evaluate Oncology Drug Dosing Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…CertaraNovember 14, 2025
ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™ Blog ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™ At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…CertaraNovember 13, 2025